KAMPOS
KAMPOS , an Italian startup company, today announced the launch of a socially-responsible, environmentally friendly line of products and accessories to celebrate the history and beauty of the Mediterranean Sea. Founded by entrepreneur Alessandro Vergano, KAMPOS’ corporate vision is to “offer luxury products with a conscience, now and for generations to come.” All products are made of recycled plastic bottles, abandoned “ghost” fishing nets, or other recycled nylon and/or organic fabrics. Every product and accessory detail have been studied and designed to be sustainable. KAMPOS’ products are recycled AND are recyclable after use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005003/en/
“Fashion companies have a tremendous platform from which to reach consumers in a positive manner, but few have embraced social issues as part of their business model,” said Vergano, KAMPOS’ co-founder and chief executive officer. “KAMPOS is different in that sustainability is at the core of everything we do from the selection from raw materials to product development to packaging. This means consumers will realize long-lasting performance of the products in which they invest because of enhanced durability and will be acting in a socially responsible manner with each purchase.”
Vergano’s vision for KAMPOS is to raise awareness worldwide of the impact of plastic pollution and abandoned fishing nets by offering sustainable, alternative high fashion solutions for consumers who share in the company’s mission. A percentage of KAMPOS’ revenues will be donated One Ocean Foundation (https://www.1ocean.org/en/ ), a non-profit founded in Porto Cervo, Sardinia. The joint effort is to accelerate solutions to ocean issues promoting a sustainable blue economy and enhancing knowledge through ocean literacy.
KAMPOS’ initial product line, which is all made in Italy, consists of swimsuits, shirts, t-shirts, perfumes, sunglasses, pareos (wraparounds) and accessories for men, women, and children. The company’s products are made of: Econyl, 100% regenerated nylon (filament) or certified GOTS (Global Organic Textile Standard) organic and biological cotton; and Newlife™, a unique, certified system of recycled polyester filament yarns that are 100% post-consumer bottle sourced, processed into a polymer through a mechanical -- not chemical -- process, and spun into yarn. No plastic is used in the packaging. The product line is now officially online at www.kampos.com and will be available for purchase in May. In June, KAMPOS plans to open its initial store in Porto Cervo, Sardinia (Italy) at the prestigious Promenade Du Port.
The name KAMPOS is an abbreviation of the Greek word HIPPO KAMPOS, which translates into Seahorse. In Rome and Greek cultures, the Seahorse was sacred to Neptune and Poseidon, the Sea Gods. It was considered a symbol of power, authority and good fortune with strong emotions and intuitions. Vergano launched KAMPOS in homage to his heritage and to celebrate the Mediterranean lifestyle.
KAMPOS’ innovative luxury fashion line includes active involvement from some of Italy’s more prominent creative and photography talent including the Carla Pozzi Agency and Art Director Roberto Da Pozzo in Milan. Additional information about KAMPOS, its products and accessories, are available on Pinterest , Instagram , Facebook and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005003/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom